Siu Fun Wong

Summary

Affiliation: Western University of Health Sciences
Country: USA

Publications

  1. ncbi Oral bexarotene in the treatment of cutaneous T-cell lymphoma
    S F Wong
    College of Pharmacy, Western University of Health Sciences, Irvine, CA, USA
    Ann Pharmacother 35:1056-65. 2001
  2. ncbi New dosing schedules of dasatinib for CML and adverse event management
    Siu Fun Wong
    Western University of Health Sciences, College of Pharmacy, Pomona, CA, USA
    J Hematol Oncol 2:10. 2009
  3. ncbi Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia
    Siu Fun Wong
    Western University of Health Sciences, College of Pharmacy, Pomona, CA 91766 1854, USA
    J Oncol Pharm Pract 15:17-27. 2009
  4. ncbi Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma
    Siu Fun Wong
    Western University College of Pharmacy, Pomona, California 91766 1854, USA
    Clin Ther 27:1942-8. 2005
  5. ncbi Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer
    Siu Fun Wong
    Western University College of Pharmacy, Pomona, CA 91766, USA
    Clin Ther 27:684-94. 2005
  6. ncbi Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy
    Siu Fun Wong
    Department of Pharmacy, University of California Irvine Medical Center, Irvine, California, USA
    Pharmacotherapy 25:372-8. 2005
  7. ncbi Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma
    Siu Fun Wong
    Western University College of Pharmacy, Pomona, CA, USA
    Ann Pharmacother 38:1655-9. 2004
  8. ncbi Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners
    Siu Fun Wong
    Department of Pharmacotherapy and Outcomes Science, Loma Linda University, Loma Linda, CA, USA
    Ann Pharmacother 45:787-97. 2011
  9. ncbi A tale of two growth factors
    John P Fruehauf
    University of California-Irvine Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA
    Pharmacotherapy 26:443-4; discussion 444. 2006
  10. ncbi Trastuzumab and cardiotoxicity: weighing the risks
    Siu-Fun Wong
    Am J Health Syst Pharm 63:525. 2006

Collaborators

Detail Information

Publications10

  1. ncbi Oral bexarotene in the treatment of cutaneous T-cell lymphoma
    S F Wong
    College of Pharmacy, Western University of Health Sciences, Irvine, CA, USA
    Ann Pharmacother 35:1056-65. 2001
    ....
  2. ncbi New dosing schedules of dasatinib for CML and adverse event management
    Siu Fun Wong
    Western University of Health Sciences, College of Pharmacy, Pomona, CA, USA
    J Hematol Oncol 2:10. 2009
    ..For patients with CP CML, a new recommended starting dose of 100 mg once daily has recently been approved. The recommended dose for patients with advanced CML or Ph+ ALL remains 70 mg twice daily...
  3. ncbi Dasatinib dosing strategies in Philadelphia chromosome-positive leukemia
    Siu Fun Wong
    Western University of Health Sciences, College of Pharmacy, Pomona, CA 91766 1854, USA
    J Oncol Pharm Pract 15:17-27. 2009
    ..Here, we review the clinical profile of dasatinib and discuss dosing strategies to manage these adverse events...
  4. ncbi Potential drug-drug interaction between interferon alfa-2b and gemfibrozil in a patient with malignant melanoma
    Siu Fun Wong
    Western University College of Pharmacy, Pomona, California 91766 1854, USA
    Clin Ther 27:1942-8. 2005
    ..Adverse events associated with IFN alfa-2b use are primarily constitutional symptoms. However, hypertriglyceridemia requiring treatment has been reported...
  5. ncbi Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer
    Siu Fun Wong
    Western University College of Pharmacy, Pomona, CA 91766, USA
    Clin Ther 27:684-94. 2005
    ..Cetuximab was also approved for administration as a single agent in the treatment of patients with EGFR-expressing, metastatic colorectal cancer who are intolerant to irinotecan-based chemotherapy...
  6. ncbi Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy
    Siu Fun Wong
    Department of Pharmacy, University of California Irvine Medical Center, Irvine, California, USA
    Pharmacotherapy 25:372-8. 2005
    ..To evaluate the effects on efficacy and safety of a formulary change from granulocyte colony-stimulating factor (G-CSF) to granulocyte-macrophage CSF (GM-CSF)...
  7. ncbi Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma
    Siu Fun Wong
    Western University College of Pharmacy, Pomona, CA, USA
    Ann Pharmacother 38:1655-9. 2004
    ..To describe 3 cases of hypertriglyceridemia associated with the use of interferon alfa (IFN-alpha) for the treatment of malignant melanoma and propose a management plan for dyslipidemia associated with interferon therapy...
  8. ncbi Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners
    Siu Fun Wong
    Department of Pharmacotherapy and Outcomes Science, Loma Linda University, Loma Linda, CA, USA
    Ann Pharmacother 45:787-97. 2011
    ..To summarize the use of tyrosine kinase inhibitors (TKIs) for treatment of patients with chronic myeloid leukemia (CML) and provide practical information for patient management...
  9. ncbi A tale of two growth factors
    John P Fruehauf
    University of California-Irvine Chao Family Comprehensive Cancer Center, Orange, CA 92868, USA
    Pharmacotherapy 26:443-4; discussion 444. 2006
  10. ncbi Trastuzumab and cardiotoxicity: weighing the risks
    Siu-Fun Wong
    Am J Health Syst Pharm 63:525. 2006